Liver Organoids, Novel and Promising Modalities for Exploring and Repairing Liver Injury

Chiyu He1,2,3,4,5,6 · Di Lu1,3,4,5,6 · Zuyuan Lin1,3,4,5,6 · Hao Chen1,3,4,5,6 · Huigang Li1,3,4,5,6 · Xinyu Yang1,3,4,5,6 · Modan Yang1,3,4,5,6 · Kai Wang1,3,4,5,6 · Xuyong Wei1,3,4,5,6 · Shusen Zheng2,4,5,7 · Xiao Xu3,4,5,6,8

Accepted: 24 September 2022 / Published online: 6 October 2022 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

The past decades have witnessed great advances in organoid technology. Liver is the biggest solid organ, performing multifaceted physiological functions. Nowadays, liver organoids have been applied in many fields including pharmaceutical research, precision medicine and disease models. Compared to traditional 2-dimensional cell line cultures and animal models, liver organoids showed the unique advantages. More importantly, liver organoids can well model the features of the liver and tend to be novel and promising modalities for exploring liver injury, thus finding potential treatment targets and repairing liver injury. In this review, we reviewed the history of the development of liver organoids and summarized the application of liver organoids and recent studies using organoids to explore and further repair the liver injury. These novel modalities could provide new insights about the process of liver injury.

Keywords Organoids · Liver · Injury · Repair · Mechanism · Model

Introduction

The incidence of liver disease is rising, accounting for approximately 2 million deaths per year worldwide [1]. Liver is the biggest solid organ, which plays a significant role in a variety of multifaceted physiological functions including metabolism, detoxification, and protein production [2–5], and it is susceptible to multiple kinds of injury and damage. The common factors induced liver injury and dysfunction include virus infection, alcohol, drug, ischemia–reperfusion, cancer, autoimmune diseases and metabolic disorder [6–12]. 2-dimensional (2D) cell line cultures and animal models are widely used for investigating the process of liver injury. However, due to the complex pathogenic mechanism of various liver injury, the traditional model cannot well simulate the injury process. Although 2D cell line cultures are established rapidly and conveniently, the lack of the organ structure and microenvironment cannot be its neglectable limitation, and the established 2D cell lines were highly genetically heterogeneous [13]. Animal models of acute liver failure tend to result in high mortality and are consuming in time, money and resources [14]. More importantly, the results of animal models may not be applicable to the situation in human body. Therefore, a new model is urgently needed to make up for these defects.
During the past decades, great advances have been made in the technology of organoids [15, 16]. The term “organoid” is defined as a 3-dimensional (3D) structure, which is grown from stem or progenitor cells which self-organizes to recapitulate tissue architecture and specific functions in vitro [17, 18]. Organoids have the spatial structure, microenvironment and stable genetic background of primary tissue owing unique advantages (Table 1). The first organoid was derived from intestinal tissue using Lgr5  + stem cells in 2009 [19]. Later, liver organoids were established in 2013 [20, 21]. Liver organoids systems were gradually applied in many fields of biomedicine. As a self-renewing culture system, organoid has a broad prospect in regeneration medicine. In this review, we reviewed and summarized recent studies using organoids to explore and repair liver injury.

**History of Liver Organoids**

The term “organoid” has been proposed for decades. It used to be defined as a sub-cellular structure [22], and was used to describe tumors with complex structures as well [23]. Since the first intestinal organoid was established, organoid was gradually regarded as a 3D culture model in vitro. To bring clarity to the term “organoid”, more than 60 experts representing 16 countries around the world reached a consensus that “organoid was a 3D structure derived from (pluripotent) stem cells, progenitor and/or differentiated cells that self-organize through cell–cell and cell–matrix interactions to recapitulate aspects of the native tissue architecture and function in vitro” [18].

The history of liver organoids can be traced back to 1985. Landry and colleagues used the spheroidal aggregate culture of hepatic cells isolated from newborn rat to cultivate a 3D culture of hepatocytes and bile duct-like cells [24]. Later, small hepatocytes (SHs), considered as progenitor cells [25, 26], were widely used in the studies of liver organoids [27, 28]. Generally, the currently widely accepted concept of organoids has been developing rapidly since 2013. Takebe and his colleagues first reported functional human liver organoids derived from induced pluripotent stem cells (iPSCs), human umbilical vein endothelial cells (HUVECs) and human mesenchymal stem cells (MSCs) [21], and modified this system using entirely iPSCs later [29]. Huch and colleagues established long-term 3D liver organoid of mouse and human adult biliary epithelial-derived progenitor cells [20, 30, 31]. Hu HL et al. cultured the hepatocytes-derived organoid system whose transcriptional profiles resembled those after partial hepatectomy [32]. In the same year, Peng WC et al. reported a liver organoids culture system derived from hepatocytes and found TNFα promoted and enabled long-term culture for more than 6 months [33]. Later, human embryonic stem cells (ESCs) and iPSCs were used to generates liver organoids which consisted of hepatocytes and cholangiocytes, recapitulating a functional bile canaliculi network [34]. These organoids were cultured in vitro to model liver disease or functional liver, and the functional liver organoids can be transplanted into mice, compensating for liver function. The comparison of current liver organoids was listed in Table 2.

In addition, the technology of organoids-on-a-chip was a milestone in the history of the liver organoids. This platform can control the biochemical microenvironment and nutrient supply using the technology of the microfluidically perfused biochip [37, 38]. And it was also used to investigate the multi-organ interactions [39]. It synergistically combined the best features of organoid and organ-on-a-chip, thus tending to develop a promising in vitro model [40, 41].

Recent years have witnessed considerable progress of liver organoids. This culture system was applied for pharmaceutical research [42–45], precision medicine, and modeling liver disease [34, 35, 45–51]. Additionally, liver organoids can also be used in exploring liver injury and repairing liver injury. This novel model could provide new insights about

### Table 1 Comparison of in vitro model systems

| Feature                          | Primary cell | Organoid | Cancer cell lines | PDX | Tumoroid |
|----------------------------------|--------------|----------|-------------------|-----|----------|
| Success rate of establishment    | ++           | +        | ++                | +   | ++       |
| Expansion                        | +            | + +      | ++                | +   | ++       |
| Cost                             | + +          | + +      | + +               | +   | ++       |
| Drug screening                   | +            | + +      | +                 | +   | ++       |
| Genetic manipulation             | +            | + +      | + +               | +   | ++       |
| Recapitulation of primary tissue functions | + + | + + | +                 | +   | ++       |
| Disease model                    | + +          | + +      | +                 | +   | ++       |
| Regenerative medicine            | + +          | + +      | n.a               | n.a | n.a      |
| Spatial structure                | +            | + +      | +                 | +   | ++       |

(++) possible, (+++) suitable, (++++) best

PDX patient derived xenograft; n.a. not applicable
| Author          | Year | Cell sources                          | Model          | Functionality/Characteristics                                                                 | Advantages                                                                 | Limitation                                                                 |
|-----------------|------|---------------------------------------|----------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Huch et al. [20]| 2013 | mouse Lgr5+ liver stem cells          | functional liver| • LDL uptake                                                                               | - broad hepatocyte phenotype in vivo                                    | - cannot rescue the enzymatic defect                                      |
|                 |      |                                       |                | • hepatocyte cytochrome p450 function                                                       | - contribution to liver function                                         | - little engraftment after transplantation                                 |
|                 |      |                                       |                | • glycogen accumulation                                                                    | - long term expansion more than 12 months                                | - lack of nonparenchymal cell                                             |
|                 |      |                                       |                | • albumin secretion                                                                        |                                                                           | - lack in vitro model                                                     |
|                 |      |                                       |                | • transduction                                                                            |                                                                           |                                                                            |
| Takebe et al.   | 2013 | human iPSCs                           | functional liver| • albumin secretion                                                                        | - rescue liver failure in vivo                                            | - different sources of cells                                              |
|                 |      | human MSCs                            |                | • drug metabolism                                                                          | - mimic liver ontogeny                                                    |                                                                            |
|                 |      | HUVECs                                |                | • vascularization                                                                          | - multiple cell types                                                    |                                                                            |
|                 |      |                                       |                | • transplantation                                                                          |                                                                           |                                                                            |
| Huch et al. [30]| 2015 | human adult bile-duct epithelial cells | functional liver| • protein production                                                                       | - long-term expansion                                                     | - lack of nonparenchymal cell                                             |
|                 |      |                                       |                | • A1AT deficiency                                                                          | - genetically stable                                                      |                                                                            |
|                 |      |                                       |                | • Alagille syndrome                                                                       | - model inherited diseases                                               |                                                                            |
|                 |      |                                       |                | • transplantation                                                                          | - highly stable at the structural level                                  |                                                                            |
| Hu HL et al.    | 2018 | mouse hepatocytes                     | functional liver| • albumin secretion                                                                        | - recapitulate the proliferative damage-response                          | - lack of nonparenchymal cell                                             |
|                 |      | human hepatocytes                     |                | • glycogen accumulation                                                                    | - long-term expansion                                                     |                                                                            |
|                 |      |                                       |                | • lipid metabolism                                                                         | - genetically stable                                                      |                                                                            |
|                 |      |                                       |                | • transplantation                                                                          | - significant graft expansion                                             |                                                                            |
| Peng WC et al.  | 2018 | primary hepatocytes                   | functional liver| • albumin secretion                                                                        | - promote expansion in vitro                                              | - lack of nonparenchymal cell                                             |
|                 |      |                                       |                | • glycogen accumulation                                                                    | - long term expansion more than 6 months                                  | - lack in vitro model                                                     |
|                 |      |                                       |                | • LDL uptake                                                                              | - significant engraftment                                                 |                                                                            |
|                 |      |                                       |                | • functional bile canaliculi                                                                | - mimic some aspects of in vivo liver regeneration                        |                                                                            |
|                 |      |                                       |                | • transplantation                                                                          |                                                                           |                                                                            |
| Ouchi et al.    | 2019 | human PSC                             | functional liver| • cytochrome p450 3A4 function                                                             | - multiple cell types                                                    | - the inter- and/or intra-batch variability                               |
|                 |      |                                       |                | • Vitamin A storage ability                                                                | - measuring organoid stiffness reflects fibrosis severity                 |                                                                            |
|                 |      |                                       |                | • inflammatory response                                                                    |                                                                           |                                                                            |
|                 |      |                                       |                | • lipid accumulation                                                                       |                                                                           |                                                                            |
| Mun SJ et al.   | 2019 | human ESC                             | functional liver| • drug metabolism                                                                          | - long-term expansion                                                     | - lack of nonparenchymal cell                                             |
|                 |      | human iPSC                            |                | • detoxifying function                                                                     | - toxicity prediction                                                     | - low level of inflammatory response                                      |
|                 |      |                                       |                | • active mitochondrial bioenergetics                                                        | - good viability after cryopreservation                                  |                                                                            |
|                 |      |                                       |                | • regenerative response                                                                    |                                                                           |                                                                            |
| Bin Ramli MN et | 2020 | human ESCs                            | functional liver| • albumin secretion                                                                        | - high-throughput                                                        | - lack of nonparenchymal cell                                             |
| et al.          |      | human iPSCs                           |                | • apolipoprotein B secretion                                                               | - consistent in shape, size and structure                                |                                                                            |
|                 |      |                                       |                | • functional bile canaliculi                                                                | - matrix-free                                                             |                                                                            |
|                 |      |                                       |                | • lipid metabolism                                                                         |                                                                           |                                                                            |
|                 |      |                                       |                | • cytochrome P450 activity                                                                  |                                                                           |                                                                            |

A1AT: Alpha-1-Antitrypsin; ESC: embryonic stem cells; HUVEC: human umbilical vein endothelial cell; iPSC: induced pluripotent stem cell; LDL: low density lipoprotein; MSC: mesenchymal stem cell; NASH: non-alcoholic steatohepatitis.
the process of liver injury. The significant events in the history of the liver organoids are summarized chronologically in Fig. 1.

Liver Organoids and Stem Cells

Organoids can be cultivated from adult stem cells (ASCs) or pluripotent stem cells [52]. And pluripotent stem cells can be divided into ESCs and iPSCs [15]. Current studies on liver organoids are mostly based on the organoids grown from adult organ-specific progenitor cells and iPSCs, while the studies derived from human ESCs were limited [46].

The origin of liver stem cell was still controversial [53], and the prevailing school of thought was listed as follows. Huch et al. deemed that Lgr5 + cells induced by liver injury acted as liver stem cells, which were able to generate hepatocytes and bile ducts [20]. Sox9 or Epcam have long been regarded as biomarker of stem/progenitor cells [54, 55]. A population of periportal hepatocytes expressing low amounts of Sox9 was observed to regenerate the liver mass after injury [56]. Researchers also found that pericentral Axin2-positive stem cells with the ability to proliferate and self-renew to maintain hepatocytes homeostasis [57]. Lin et al. revealed that hepatocytes with high telomerase expression were distributed throughout the liver lobule, which were able to regenerate hepatocytes, self-renew and differentiate to hepatocyte clones [58]. Stem cells or progenitor cells is the origin of liver organoids. Lgr5 + cells were able to form organoids, while the ability to form organoids of other cell subsets and the difference between these derivative organoids awaits further investigation.

The technology of generating iPSCs has greatly promoted the study of organoids. In many aspects including morphology, ability of proliferating, gene expression, and telomerase activity, human iPSCs presented similarly to human ESCs [59]. Takebe and colleagues reported a functional human liver organ from iPSCs for the first time [21]. They cultivated three kinds of cells including hepatic endoderm cells from human iPSCs, HUVECs and human MSCs together to recapitulate the organogenetic interactions. Notably, after transplantation the liver organoids can generate vessels and connected quickly with host vasculature within 48 h [21]. This finding of organoids transplantation showed potential application to study regenerative medicine. Later, Takebe’s team also generated successfully human liver buds entirely derived from iPSCs [29], dealing with the problem of figuring out and maintaining the suitable conditions for the different cells in the same coculture system.

To sum up, stem cells is the fundament for organoids research, thus the liver stem cell is highly needed to identified and clarified in the future. In addition, the process of culturing organoids revealed the proliferation and differentiation of stem cells, and liver organoids can recapitulate liver development in vivo to some degree [60].

Current Application of Liver Organoids

Pharmaceutical Research

Recently, pharmaceutical research is costing and inefficient, and clinical trials of many drugs that are effective in animals and cell lines have often failed, partially due to the traditional model cannot accurately recapitulate in vivo drug efficacy. Therefore, applying organoids in pharmaceutical research is a popular direction.

Organoids model have a promising potential in anti-cancer drug screening, which can be derived from cancer tissue and is called as tumoroids. Based on organoids model, a study reported that the ERK inhibitor SCH772984 was identified to be a potential therapeutic drug against primary liver cancer [61]. Nuciforo et al. used organoids derived from tumor needle biopsies to test sensitivity to sorafenib, which showed the potential treatment strategy for those patients who didn’t undergo surgery [62].
reported the model of hepatoblastoma organoids and found that JQ1 had more killing effects of tumoroids compared to adjacent non-tumor liver organoids [44]. However, there is a long way to go before putting the screening results of organoids into clinical practice, because some screening drugs were not approved for use in relevant disease. Although the result was convincing and reliable, caution should be exercised regarding off-label drug use, and side effects need to be considered.

Due to its complex pathogenesis, the genetic disease is hardly modeled. While, organoids inherit the genetic background of the primary tissue and recapitulate native tissue architecture and function to the greatest extent, which makes it become a direct and intuitive platform to explore disease mechanism and discovery drugs. A group established organoids model generated from patients with polycystic liver disease, and the experimental cystic fibrosis drug VX809 was found to increase cystic fibrosis transmembrane regulator (CFTR) function in vitro and may have therapeutic effect in cystic fibrosis [45].

To sum up, the pharmaceutical research of liver organoid mainly focuses on drug effectiveness and drug toxicity. Especially in drug discovery, a big-scale compound screening can be conducted based on liver organoids model. Liver organoids show their powerful ability to mimic in vivo condition, have more advantages compared to the other models and have a better application prospect.

**Precision Medicine and Biobank**

Due to the variance of individuals, the treatment effects of the same therapy strategy are inconsistent particularly in cancer cases. In recent years, precision medicine is highly being recommended to improve the prognosis and increase the therapeutic effect in clinical practices. However, there are two notable challenges in establishing precision models: maintaining the heterogeneity in different individual tumors and restructuring of the tumor microenvironment [63]. Organoids have been considered as the convincing and powerful preclinical model in precision therapy [64]. The organoids of a patient-specific tumor can be cultivated from primary liver cancer, and it can recapitulate the expression profile and the histology of the parental tumor, and retain the genetic alterations [61]. The common clinical drugs can be applied in organoids and the optimal treatment options can be decided after evaluating the efficacy and side effects. And specific therapy strategies can be determined according to the molecular subtypes of patients.

Building up a biobank containing abundant organoid samples is one of the future trends of applications. The biobank of rich samples can facilitate the establishment of screening platforms which cover a wide range of global populations genetic variance [65]. Biobanks of primary colorectal tumoroids had been established [66, 67]. The genetic features of the primary tumors and these histopathological features were stored and different molecular subtypes and clinical stages were covered. However, due to its unsatisfied success rate, the biobank of liver organoids was limited. A group cultivated liver tumor organoids from HCC needle biopsies, and it had about 26% success rate (10/38). There was not a statistically significant correlation between the clinically characteristics of patients and the success rate for generating organoids. On the contrary, there was a strong correlation with the pathological condition and KI-67 [62]. Therefore, improving the success rate for generating organoids was also an urgent need in the process of building biobanks.

**Exploring Liver Injury using Organoids**

As mentioned above, the technology of liver organoids can be applied in pharmaceutical research and precision medicine, and each application has promising prospects. Additionally, the liver organoids can be used in exploring liver injury and finding potential treatment strategies. As reported previously, many organoids derived from organs except liver were already applied for exploring organ injury, including stomach [68], lung [69–71], intestine [72], heart [73], brain [74], kidney [75] and colon [71, 76] (Table 3). The liver organoids hold great promise for investigating liver injury, and the main reported studies are listed as follows.

**Infection-induced Liver Injury**

Hepatitis virus is the major cause of infection-induced liver injury. Hepatitis B virus (HBV) infection is not a neglectable challenge with over 240 million infected people globally [77], and the number of people infected with the hepatitis C virus (HCV) has reached 115 million [78]. Primary human hepatocytes (PHHs) were previously considered as the most suitable for hepatitis virus study [79]. However, it was difficult to obtain and maintain their growth. Establishing a novel and stable platform was needed. As far as we know, Nie and colleagues used iPSC-derived organoids to explore the HBV-induced liver injury for the first time. After infected by HBV, these liver organoids showed hepatic dysfunction, presenting down-regulation of hepatic gene expression, releasing early acute liver failure markers and alteration of hepatic ultrastructure [80]. Furthermore, liver organoids can be used for the study of hepatocarcinogenesis based on HBV-related liver injury [81, 82]. While, the researches using 3D cell culture systems to model HCV infection were more focused on HCV entry and revealed novel findings which were not seen in 2D cell lines [83, 84]. A recent study successful recapitulated the hepatitis E virus (HEV) infection in liver organoids and further found two potent HEV inhibitors [85].
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the global pandemic of coronavirus disease 2019 (COVID-19). The virus not only resulted in respiratory failure but also caused multi-organ injury including liver, gut, heart, and pancreas [86–88]. At present, the liver organoids have been applied in the study of SARS-CoV-2-induced liver injury [89, 90]. Zhao found these liver organoids were susceptible to SARS-CoV-2 and supported robust viral replication. The genes relating to tight junction formation and bile acid transportation were disordered and the relevant functions were impaired by SARS-CoV-2 infection [90]. These findings may better the understanding towards this disease and provide potential treatment strategies against COVID-19.

To sum up, these novel models provided a stable and reliable platform to explore infection-induced liver injury, and its 3D structure bettered the recapitulation of interaction between virus-cell and cell–cell during the process of infection.

### Hypoxia-induced Liver Injury

Hypoxia is a pathological process of abnormal changes in tissue metabolism, function and morphology due to insufficient oxygen supply or oxygen use disorder. It is a common pathological state in various clinical diseases and even in medical treatment. Recently, a group established 15 organoids cultures derived from human liver biopsies [91]. The organoids were observed having functional ion channels including CFTR and anoctamin-1 (ANO1). This model was established to mimic hypoxia-related biliary injury during liver transplantation (LT). During hypoxia, the physiological function of CFTR and ANO1 was inhibited, and an AMP kinase inhibitor can restore the function of these two ion channels partially. Furthermore, the resistance of organoids to bile cytotoxicity was also reduced after hypoxia, thus increasing cell death. Accordingly, organoid is a powerful and reliable platform to study cholangiocyte anion exchange channels and their direct changes induced by hypoxia. In 3D cell culture systems, Liu et al. found that hypoxia was
capable of inducing EMT and cancer cell stemness through upregulating the expression of Twist1 and Bmi1 [92]. In conclusion, the new mechanism of hypoxia-induced liver injury can be discovered based on organoids model and the potential therapeutic strategies tend to be developed to repair injury.

Drug-induced Liver Injury

Drug-induced liver injury (DILI) is one of the critical challenges in drug development, and it is also associated with considerable morbidity and mortality [93]. Leite and colleagues cultivated liver organoids grown from HepaRG cells and Hepatic Stellate Cells (Hep/HSC) [94]. After a 24 h Acetaminophen (APAP) exposure, hepatocytes in the periphery of the organoid disappeared, and apoptotic cells remained surrounding the HSC core, showing the previously reported path of APAP-induced liver injury [95]. HSC-associated mRNAs including COL1A1, COL3A1 and LOXL2 were detected, presenting a dose-dependent up-regulation tendency only in Hep/HSC organoids and showing that HSC activation played a role in liver injury. The HSC activation role of APAP was confirmed in vivo in mice. They also detected the effects of pro-fibrotic compounds including Allyl alcohol and Methotrexate in liver organoids, and the organoids displayed fibrotic feature [94]. To sum up, these novel organoids were the first platform to study hepatocyte-dependent HSC activation, and provided a powerful tool to find underlying mechanism to prevent and reverse DILI.

Alcohol-induced Liver Injury

Excessive alcohol consumption is the leading cause of liver-related deaths in western countries. Oxidative stress and mitochondrial disorder were the major factors to promote steatosis in alcoholic liver disease (ALD) [7]. Based on the model of liver organoids, a study showed that after EtOH treatment for 7 days, the CYP2E1 activity was increased [49]. The up-regulated secretion of ALT, AST and LDH, and the reduction in cell viability revealed the damage in liver organoids. In addition, the gene expression of fibrogenic markers including LOXL2, COL1A1, COL3A1, ACTA2 and TGFβ1 were up-regulated, which showed the fibrogenic responses to EtOH in organoids model. The measurement of reactive oxygen species (ROS) and glutathione (GSH) in organoids revealed that oxidative stress was enhanced after EtOH treatment. In addition, inflammation also has been thought to play a key role in the pathogenesis of ALD [96]. The release of inflammatory mediators was measured in the EtOH-treated liver organoid, and both cytokines relative to chemokines and interleukins increased [49]. This reliable and practical in vitro system simulated the pathophysiology of ALD for the first time, and provided a powerful platform for exploring the underlying mechanisms as well.

Non-alcoholic Fatty Liver Disease

With the rise of patients with obesity and type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide [97, 98], which progresses from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), eventually severe liver fibrosis, cirrhosis and hepatocellular carcinoma [99, 100]. However, current NAFLD models based on PHHs and cancer cell lines cannot meet research needs, and the lack of appropriate in vitro human-based in vitro model hindered the deep understanding of NAFLD progression [101]. Mun SJ et al. reported a PSC-derived liver organoid model which recapitulated human hepatic steatosis phenotypes [36]. The model showed the functionality of lipid accumulation. However, it is insufficient to induce inflammation in the liver due to the lack of nonparenchymal cells. Ouchi and colleagues used human pluripotent stem cells to culture multi-cellular human liver organoids composed of hepatocyte-, stellate- and Kupffer-like cells which recapitulated key features of steatosis, inflammation and fibrosis phenotypes in a successive manner. Furthermore, they evaluated the fibrosis severity by measuring liver organoids stiffness [35]. Pingitore and colleagues cultured 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) in an artificially determined ratio. When exposed to free fatty acids (FFA), the spheroids developed accumulations of fat and collagen, which can be rescued by liraglutide or elafibranor. Furthermore, based on organoids-on-chip system derived from iPSCs [41] or HepaRG [102], high-throughput drug screening potentially accelerated the NAFLD drug development. Based on NASH organoids model, Taesik et al. found that anti-CD47 antibody might be a new therapeutic option for NASH and liver fibrosis [103]. Ramli and colleagues used ESCs and iPSCs to establish liver organoids, which can be used to model NASH. After the incubation of FFA, the structure changes can be observed, including decay of bile canaliculi network and ductular reactions. The gene expression signatures of NASH organoid were similar to those of liver tissues from patients with NASH [34]. To sum up, these models recapitulated the spatial structure and its reaction toward FFA, while the cell types were limited. The ideal NASH model should contain hep-orgs, stellate- and Kupffer cells, which played a key role in the progression of NAFLD [104].

Application of Organoids in Regenerative Medicine

As mentioned above, the model of liver organoids was a reliable and stable platform for exploring liver injury, which shed more light on new treatment strategies. Apart from this
perspective, the liver organoids grown from in vitro systems can be used to repair liver injury in regenerative medicine.

The ideal pattern of regenerative medicine contains three steps: culturing tissues or organs in vitro, transplanting functional tissue into body and correcting the pre-existing disorder. The cell from a healthy donor or the gene edited cell from patients may be the sources of organoids for regenerative medicine purposes [65]. Transplantation of in-vitro-generated organoids is an application with great prospects, and its feasibility is the primary and basic consideration. And vascularization and immune response are critical to success rate of transplantation. Takebe et al. reported that after transplanting into nude mice, the organoids could reconstruct functional vessels and rescued the drug-induced liver injury [105]. A group successfully transplanted human iPSC-derived liver organoids into immunocompetent mice by encapsulating organoids in biocompatible hydrogel capsules [106]. These capsules were able to prevent direct immune cell rejection but it did not mean the total elimination of immune response. Although transplantation in animal models mimics the condition in vivo, it did not always predict the real outcomes in practice [107]. Notably, Sampaziotis and colleagues reported a groundbreaking finding in 2021 [108]. Gallbladder organoids were injected into the intrahepatic ducts of human livers and then delivered into a terminal branch of intrahepatic ducts. The bile PH was measured less than 7.5 before the experiment, which meant ischemic duct injury [109]. After treatment, the pH

**Fig. 2** Applications of liver organoids. The current application of liver organoids mainly focuses on establishing the biobank of organoids and testing drug effectiveness and drug toxicity. Some studies used organoids to constructed diseases models in vitro and exploring the underlying mechanism of relevant diseases. Furthermore, genetically modified organoids can be used as a source for regenerative medicine purposes. In addition, the liver organoids can expand massively in vitro and be transplanted back for compensating the liver function. Abbreviations: NAFLD, non-alcoholic fatty liver disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
and volumes of bile from injected duct were higher, and
the injected duct did not show evidence of cholangiopathy,
which meant that organoids could maintain their function
and repair bile ducts injury [108].

To sum up, organoid technology showed a lot of prospects
in regenerative medicine. The future study can apply liver
organoids to release the biliary complication, improve liver
function of the Small-for-size Syndrome and better the qual-
ity of expanded criteria donors for expanding the liver donor
pool, though there is a long way to go before the mature
clinical application.

Future Direction

Recent years have witnessed great advances in the field of
liver organoids. Enormous studies have revealed the prom-
ising potential of organoids in biomedicine researches
including disease modeling, mechanisms exploring, preci-
sion medicine, regenerative medicine and pharmaceutical
researches (Fig. 2) [17, 63, 65, 108, 110]. However, this
technology also has its drawbacks and limitations, and possi-
bile solutions are also discussed below.

Firstly, there are some stumbling blocks in the process of
cultivating organoids. Establishing adult stem cell-derived
liver organoids needs fresh patient-origin tissue from surgi-
cal resection or needle biopsy, and the availability of patient
tissue may be limited. And the amount of freshly-isolated
hepatocytes may be limited due to the tissue size, and the
amplification of large number of cells in spinner flasks may
be cost-prohibitive [111]. Remarkably, the success rate of
establishment of liver organoids is a matter of urgent con-
cern to us, however it is lower than those of other organ
organoids to some extent. In addition, although the main
steps to grow liver organoids are similar in different labo-
rites, there are still not standardized and consensual proto-
cols, especially in terms of what growth factors are used
to induce differentiation, which may result in different cell
maturity further leads to deviation of results. Matrigel is
the most commonly utilized matrix, and the ingredients
are complex and heterogeneous. Therefore, the appropri-
ate extracellular matrix also needs to be identified [112].
Currently, a group reported a nanofibrillar hydrogel with
controllable stiffness for organoids culture [113], and it is
highly needed to exploit a standard biomimetic material of
known composition in the future.

Secondly, the ability of mimicking the real organs can
be further improved. Although liver organoids show great
advantages in cell types and spatial structures compared
with conventional 2D cultures, it cannot reproduce every
cell type in liver tissue and simulate the real and dynamic
cell–cell interactions totally. The nature of their random
growth makes it difficult to precisely control their shape
and microenvironment, which limits their use in the clinic
and lab [114, 115]. Fortunately, a current study developed
bioengineering strategies to induce the deterministic forma-
tion of intestinal organoids [116]. The standard and uniform
liver organoids are awaiting further investigation. In addi-
tion, the immune-checkpoint inhibitors have revolutionized
the clinical guidelines of HCC treatment in the past 5 years
[117]. The organoid derived from HCC lacks the immune
microenvironment, and this has greatly hindered the under-
standing on the mechanism of immune responses and eva-
sion. Co-culture of organoids with immune-cells may be a
promising solution to deal with the problem.

Thirdly, the variety of models based on liver organoids
can be much richer, and organoids-on-a-chip can simulate
more disease models in vitro. Although there are already
some novel models based on organoids for exploring liver
injury, the amount of these models is still limited com-
pared with animal models and traditional 2D cell models.
IRI is a significant type of liver injury and often occurs
after surgical procedures such as hepatic resection and LT
[118]. As far as we concerned, IRI is an important risk
factor of early allograft dysfunction, resulting in the failure
of LT [119, 120]. A deep understanding of IRI remains
challenging, and the mechanism of IRI is still not well
understood [121–123]. At present, researchers investigate
the mechanism of IRI by animal models and the in vitro
model of IRI [124, 125]. However, the emergence and
progress of organoids-on-a-chip gives it more possibil-
ity to refine existed models and establish more disease
models in vitro. The most remarkable advantages are its
controllable microenvironment and nutrient supply using
the technology of the microfluidically perfused biochip.
Theoretically speaking, the technique is able to mimic the
process of ischemia and reperfusion. However, an in vitro
model of liver IRI has not been established in organoids.
We hold the view that with the development of organoids-
on-a-chip technology, the organoid model of liver IRI may
be successfully established in the near future and widely
applied.

In conclusion, as a newly developed platform, organoid
has great application potential and prospects, although it is
still not perfect and needs to be improved in some aspects.
In the future, it is prone to be a usual and powerful model
for biomedicine researches.

Abbreviations
ALD: Alcoholic liver disease; ANO1: Anoctamin-1;
APAP: Acetaminophen; ASCs: Adult stem cells; CFTR: Cystic
fibrosis transmembrane regulator; COVID-19: Corona virus disease
2019; DILI: Drug-induced liver injury; ESCs: Embryonic stem cells;
FFA: Free fatty acids; GSH: Glutathione; HBV: Hepatitis B virus;
HCV: Hepatitis C virus; HEV: Hepatitis E virus; HSC:Hep/HSC:
Hep-
aRG cells and hepatic stellate cells; iPSC: Induced pluripotent stem
cell; IRI: Ischemia-reperfusion injury; LD: Low density lipoprotein;
LT: Liver transplantation; NAFLD: Non-alcoholic fatty liver dis-
ease; NASH: Non-alcoholic steatohepatitis; PHHs: Primary human

© Springer
hepatocytes; ROS: Reactive oxygen species; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SHs: Small hepatocytes; TNF: Tumor necrosis factor; 2D: 2-Dimensional; 3D: 3-dimensional

Acknowledgements We thank all members of Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province for helpful suggestions regarding the manuscript. The figures in our review were created with BioRender.com.

Author Contributions HCY and LD performed the literature review and drafted the manuscript. LZY, CH, LHG, YXY and ZSS performed the literature review, drafted and revised the manuscript. WK and WXY reviewed and edited the manuscript. XX and ZSS supervised, drafted and revised the manuscript.

Funding This work was supported by the National Key Research and Development Program of China (No. 2021YFA1100500), the Key Program, National Natural Science Foundation of China (No. 81930016), and the Young Program of National Natural Science Funds (No. 82000617).

Data Availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code Availability Not applicable.

Declarations

Ethics Approval Not applicable.

Consent to Participate Not applicable.

Consent for Publication Not applicable.

Competing Interests The authors declare that they have no competing interests.

References

1. Asrani, S. K., Devabhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of Hepatology, 70, 151–171.
2. Laker, M. F. (1990). Liver function tests. BMJ, 301, 250–251.
3. Trefis, E., Gannon, M., & Wasserman, D. H. (2017). The liver. Current Biology, 27, R1147–R1151.
4. Stanger, B. Z. (2015). Cellular homeostasis and repair in the mammalian liver. Annual Review of Physiology, 77, 179–200.
5. Halpern, K. B., Shenhav, R., Matcovitch-Natan, O., Toth, B., Lemze, D., Golan, M., et al. (2017). Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature, 542, 352–356.
6. Manka, P., Verheyen, J., Gerken, G., & Canbay, A. (2016). Liver failure due to acute viral hepatitis (A-E). Visceral Medicine, 32, 80–85.
7. Louvet, A., & Mathurin, P. (2015). Alcoholic liver disease: Mechanisms of injury and targeted treatment. Nature Reviews. Gastroenterology & Hepatology, 12, 231–242.
8. Leise, M. D., Poterucha, J. J., & Talwalkar, J. A. (2014). Drug-induced liver injury. Mayo Clinic Proceedings, 89, 95–106.
9. Nastos, C., Kalimeris, K., Papoutsidakis, N., Tassoulis, M. K., Lykoudis, P. M., Theodoraki, K., et al. (2014). Global consequences of liver ischemia/reperfusion injury. Oxidative Medicine and Cellular Longevity, 2014, 906965.
10. Dar, W. A., Sullivan, E., Bynon, J. S., Eltzschig, H., & Ju, C. (2019). Ischaemia reperfusion injury in liver transplantation: Cellular and molecular mechanisms. Liver International, 39, 788–801.
11. Liaskou, E., Hirschfeld, G. M., & Gershwin, M. E. (2014). Mechanisms of tissue injury in autoimmune liver diseases. Seminars in Immunopathology, 36, 553–568.
12. Elkrief, L., Rautou, P. E., Sarin, S., Valla, D., Paradis, V., & Moreau, R. (2016). Diabetes mellitus in patients with cirrhosis: Clinical implications and management. Liver International, 36, 936–948.
13. Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hino-hara, K., et al. (2018). Genetic and transcriptional evolution alters cancer cell line drug response. Nature, 560, 325–330.
14. Inomata, K., Tajima, K., Yagi, H., Higashi, H., Shimoda, H., Matsubara, K., et al. (2018). A pre-clinical large animal model of sustained liver injury and regeneration stimulus. Science and Reports, 8, 14987.
15. Clevers, H. (2016). Modeling development and disease with organoids. Cell, 165, 1586–1597.
16. Simian, M., & Bissell, M. J. (2017). Organoids: A historical perspective of thinking in three dimensions. Journal of Cell Biology, 216, 31–40.
17. Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. Science, 345, 1247125.
18. Marsee, A., Roos, F. J. M., Verstegen, M. M. A., Consortium HPBO, Gehart, H., de Koning, E., et al. (2021). Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell, 28, 816–832.
19. Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., et al. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, 459, 262–265.
20. Much, M., Dorrell, C., Boj, S. F., van Es, J. H., Li, V. S., van de Wetering, M., et al. (2013). In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature, 494, 247–250.
21. Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., et al. (2013). Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature, 499, 481–484.
22. Duryee, W. R., & Doherty, J. K. (1954). Nuclear and cytoplasmic reorganization, biomatrix deposition, and maintenance of functional activities. Journal of Cell Biology, 101, 914–923.
23. Heller, D. S., Frydman, C. P., Gordon, R. E., Jagirdar, J., & Schwartz, I. S. (1991). An unusual organoid tumor. Alveolar soft part sarcoma or paraganglioma? Cancer, 67, 1894–1899.
24. Landry, J., Bernier, D., Ouellet, C., Goyette, R., & Marceau, N. (1985). Spheroidal aggregate culture of rat liver cells: Histotypic reorganization, biomatrix deposition, and maintenance of functional activities. Journal of Cell Biology, 101, 914–923.
25. Mitaka, T., Mikami, M., Sattler, G. L., Pitot, H. C., & Mochizuki, Y. (1992). Small cell colonies appear in the primary culture of adult rat hepatocytes in the presence of nicotinamide and epidermal growth factor. Hepatology, 16, 440–447.
26. Mitaka, T., Sato, F., Mizaguchi, T., Yokono, T., & Mochizuki, Y. (1999). Reconstruction of hepatic organoid by rat small hepatocytes and hepatic nonparenchymal cells. Hepatology, 29, 111–125.
27. Harada, K., Mitaka, T., Miyamoto, S., Sugimoto, S., Ikeda, S., Takeda, H., et al. (2003). Rapid formation of hepatic organoid in collagen sponge by rat small hepatocytes and hepatic nonparenchymal cells. Journal of Hepatology, 39, 716–723.
cancers derived from tumor needle biopsies. *Cell Reports, 24*, 1363–1376.
63. Xia, X., Li, F., He, J., Aji, R., & Gao, D. (2019). Organoid technology in cancer precision medicine. *Cancer Letters, 457*, 20–27.
64. Li, M., & Izipisu Belmonte, J. C. (2019). Organoids - preclinical models of human disease. *New England Journal of Medicine, 380*, 569–579.
65. Rossi, G., Manfrin, A., & Lutolf, M. P. (2018). Progress and potential in organoid research. *Nature Reviews Genetics, 19*, 671–687.
66. Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., et al. (2016). A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. *Cell Stem Cell, 18*, 827–838.
67. van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., et al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell, 161*, 933–945.
68. Bartfeld, S., Bayram, T., van de Wetering, M., Huch, M., Begeth, H., Kujala, P., et al. (2015). In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. *Gastroenterology, 148*, 126–136 e126.
69. Quantius, J., Schmoldt, C., Vazquez-Arendariz, A. I., Becker, C., El Agha, E., Wilhelm, J., et al. (2016). Influenza virus infects epithelial stem/progenitor cells of the distal lung: Impact on Fgfr2b-driven epithelial repair. *PLoS Pathogens, 12*, e1005544.
70. Li, X., Wu, J., Sun, X., Wu, Q., Li, Y., Li, K., et al. (2020). Autophagy reprograms alveolar progenitor cell metabolism in response to lung injury. *Stem Cell Reports, 14*, 420–432.
71. Han, Y., Duan, X., Yang, L., Nilsson-Payant, B. E., Wang, P., Duan, F., et al. (2021). Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. *Nature, 589*, 270–275.
72. Lu, R., Voigt, R. M., Zhang, Y., Kato, I., Xia, Y., Forsyth, C. B., et al. (2017). Alcohol injury damages intestinal stem cells. *Alcoholism, Clinical and Experimental Research, 41*, 727–734.
73. Voges, H. K., Mills, R. J., Elliott, D. A., Parton, R. G., Porrello, E. R., & Hudson, J. E. (2017). Development of a human cardiac organoid injury model reveals innate regenerative potential. *Development, 144*, 1118–1127.
74. Davaud, N., Chevalier, C., Friedel, R. H., & Zou, H. (2019). Distinct vulnerability and resilience of human neuroprogenitor subtypes in cerebral organoid model of prenatal hypoxic injury. *Frontiers in Cellular Neuroscience, 13*, 336.
75. Digby, J. L. M., Vanichapol, T., Zerpe, J., et al. (2020). Evaluation of cisplatin-induced injury in human kidney organoids. *American Journal of Physiology Renal Physiology, 318*, F971–F978.
76. d’Aldebert, E., Quaranta, M., Sebert, M., Bonnet, D., Kirzin, S., Portier, G., et al. (2020). Characterization of human colon organoids from inflammatory bowel disease patients. *Frontiers in Cell and Developmental Biology, 8*, 363.
77. Ott, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012). Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine, 30*, 2212–2219.
78. Gower, E., Estes, C., Blach, S., Razavi-Shirazi, K., & Razavi, H. (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. *Journal of Hepatology, 61*, S45–S7.
79. Gural, N., Mancio-Silva, L., He, J., & Bhattacharjee, S. N. (2018). Engineered livers for infectious diseases. *Cellular and Molecular Gastroenterology and Hepatology, 5*, 131–144.
80. Nie, Y. Z., Zheng, Y. W., Miyakawa, K., Murata, S., Zhang, R. R., Sekine, K., et al. (2018). Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells. *EBioMedicine, 35*, 114–123.
81. Rao, S., Hossain, T., & Mahmoudi, T. (2021). 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis. *Cancer Letters, 506*, 35–44.
82. Torresi, J., Tran, B. M., Christiansen, D., Earnest-Silveira, L., Schwab, R. H. M., & Vincan, E. (2019). HBV-related hepatocarcinogenesis: The role of signalling pathways and innovative ex vivo research models. *BMC Cancer, 19*, 707.
83. Collett, S., Torresi, J., Silveira, L. E., Truong, V. K., Christiansen, D., Tran, B. M., et al. (2021). Investigating virus-host cell interactions: Comparative binding forces between hepatitis C virus-like particles and host cell receptors in 2D and 3D cell culture models. *Journal of Colloid and Interface Science, 592*, 371–384.
84. Baktash, Y., Madhav, A., Coller, K. E., & Randall, G. (2018). Single particle imaging of polarized hepatoma organoids upon hepatitis C virus infection reveals an ordered and sequential entry process. *Cell Host & Microbe, 23*, 382–394 e385.
85. Li, P., Li, Y., Wang, Y., Liu, J., Lavrijsen, M., Li, Y., et al. (2022). Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. *Science Advances, 8*, eabj5908.
86. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet, 395*, 507–513.
87. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Nature, 579*, 120–123.
88. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A Novel Coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine, 382*, 727–733.
89. Yang, L., Han, Y., Nilsson-Payant, B. E., Gupta, V., Wang, P., Duan, X., et al. (2020). A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. *Cell Stem Cell, 27*, 125-136 e127.
90. Zhao, B., Ni, C., Gao, R., Wang, Y., Yang, L., Wei, J., et al. (2020). Recapitulation of SARS-CoV-2 infection and cholangioocyte damage with human liver ductal organoids. *Protein & Cell, 11*, 771–775.
91. Roos, F. J. M., Bijvelds, M. J. C., Verstegen, M. A. M., Roest, H. P., Metselaar, H. J., Polak, W. G., et al. (2021). Impact of hypoxia and AMPK on CPT1-mediated bicarbonate secretion in human cholangiocyte organoids. *American Journal of Physiology Gastrointestinal and Liver Physiology, 320*, G741-g752.
92. Liu, K., Sun, B., Zhao, X., Wang, X., Li, Y., Qiu, Z., et al. (2015). Hypoxia promotes vasculosgenic mimicry formation by the Twist1-Bmi1 connection in hepatocellular carcinoma. *International Journal of Molecular Medicine, 36*, 783–791.
93. Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., et al. (2015). Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. *Gastroenterology, 148*, 1340-1352 e1347.
94. Leite, S. B., Roosens, T., El Taghdouini, A., Mannerts, I., Smout, A. J., Najimi, M., et al. (2016). 3D human hepatocyte organoids model enables testing of drug-induced liver fibrosis in vitro. *Biomaterials, 78*, 1–10.
95. Nakagawa, H., Maeda, S., Hikiba, Y., Ohmura, T., Shibata, W., Yanai, A., et al. (2008). Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. *Gastroenterology, 135*, 1311–1321.
96. Xu, M. J., Zhou, Z., Parker, R., & Gao, B. (2017). Targeting inflammation for the treatment of alcoholic liver disease. *Pharmacology & Therapeutics, 180*, 77–89.
97. Younossi, Z. M. (2019). Non-alcoholic fatty liver disease - A global public health perspective. *Journal of Hepatology*, 70, 531–544.
98. Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A. A. (2022). The prevalence and incidence of NASH worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*, 7(9), 851–861.
99. Cohen, J. C., Horion, J. D., & Hobbs, H. H. (2011). Human fatty liver disease: Old questions and new insights. *Science*, 332, 1519–1523.
100. Farrell, G. C., & Larter, C. Z. (2006). Nonalcoholic fatty liver disease: From steatosis to cirrhosis. *Hepatology*, 43, S99–S112.
101. Boeckmans, J., Natale, A., Buyk, Y., Rogiers, V., De Kock, J., Vanhaecke, T., et al. (2018). Human-based systems: Mechanistic NASH modelling just around the corner? *Pharmacological Research*, 134, 257–267.
102. Teng, Y., Zhao, Z., Tasnim, F., Huang, X., & Yu, H. (2021). A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. *Biomaterials*, 275, 120094.
103. Gwag, T., Ma, E., Zhou, C., & Wang, S. (2022). Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models. *Liver International*, 42, 829–841.
104. Nuciforo, S., & Heim, M. H. (2021). Organoids to model liver disease. *JHEP Reports: Innovation in Hepatology*, 3, 100198.
105. Takebe, T., Enomura, M., Yoshizawa, E., Kimura, M., Koike, H., Ueno, Y., et al. (2015). Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation. *Cell Stem Cell*, 16, 556–565.
106. Song, W., Lu, Y. C., Frankel, A. S., An, D., Schwartz, R. E., & Ma, M. (2015). Engraftment of human induced pluripotent stem cell-derived hepatocytes in immunocompetent mice via 3D co-aggregation and encapsulation. *Science and Reports*, 5, 16884.
107. Arber, C., Brenner, M. K., & Reddy, P. (2013). Mouse models in bone marrow transplantation and adoptive cellular therapy. *Seminars in Hematology*, 50, 131–144.
108. Sampaziotis, F., Muraro, D., Tysoe, O. C., Sawiak, S., Beach, T. E., Godfrey, E. M., et al. (2021). Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. *Science*, 371, 839–846.
109. Watson, C. J. E., Kosmoliaptsis, V., Pley, C., Randle, L., Fear, C., Crick, K., et al. (2018). Observations on the ex situ perfusion of livers for transplantation. *American Journal of Transplantation*, 18, 2005–2020.
110. Lai, H. C. H., Kransenburg, O., Xiao, H., & Yu, J. (2020). Organoid models of gastrointestinal cancers in basic and translational research. *Nature Reviews. Gastroenterology & Hepatology*, 17, 203–222.
111. Schneeberger, K., Sanchez-Romero, N., Ye, S., van Steenbeek, F. G., Oosterhoff, L. A., Pla Palacin, I., et al. (2020). Large-scale production of LGR5-positive bipotential human liver stem cells. *Hepatology*, 72, 257–270.
112. Shiota, J., Samuelson, L. C., & Razumilava, N. (2021). Hepatobiliary organoids and their applications for studies of liver health and disease: Are we there yet? *Hepatology*, 74(4), 2251–2263.
113. Prince, E., Cruickshank, J., Ba-Alawi, W., Hodgson, K., Haight, J., Tobin, C., et al. (2022). Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids. *Nature Communications*, 13, 1466.
114. Sasai, Y. (2013). Next-generation regenerative medicine: Organogenesis from stem cells in 3D culture. *Cell Stem Cell*, 12, 520–530.
115. McCauley, H. A., & Wells, J. M. (2017). Pluripotent stem cell-derived organoids: Using principles of developmental biology to grow human tissues in a dish. *Development*, 144, 958–962.
116. Gjorv, S., Nikolaeff, M., Brown, T. E., Mitrofanova, O., Brandenberg, N., DelRio, F. W., et al. (2022). Tissue geometry drives deterministic organoid patterning. *Science*, 375, eaa9021.
117. Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferr, V., Pinato, D. J., et al. (2022). Immunotherapies for hepatocellular carcinoma. *Nature Reviews Clinical Oncology*, 19, 151–172.
118. Peralta, C., Jimenez-Castro, M. B., & Gracia-Sancho, J. (2013). Hepatic ischemia and reperfusion injury: Effects on the liver sinusoidal milieu. *Journal of Hepatology*, 59, 1094–1106.
119. Zhou, J., Chen, J., Wei, Q., Saeb-Parsy, K., & Xu, X. (2020). The role of ischemia/reperfusion injury in early hepatic allograft dysfunction. *Liver Transplantation*, 26, 1034–1048.
120. Wang, K., Lu, D., Liu, Y., Li, W., Zhuang, L., Ma, Z., et al. (2021). Severity of early allograft dysfunction following donation after circulatory death liver transplantation: A multicentre study. *Hepato-biliary Surgery and Nutrition*, 10, 9–19.
121. Li, J., Li, R. J., Lv, G. Y., & Liu, H. Q. (2015). The mechanisms and strategies to protect from hepatic ischemia-reperfusion injury. *European Review for Medical and Pharmacological Sciences*, 19, 2036–2047.
122. Jin, L. M., Liu, Y. X., Cheng, J., Zhou, L., Xie, H. Y., Feng, X. W., et al. (2022). The effect of SphK1/S1P signaling pathway on hepatic sinus microcirculation in rats with hepatic ischemia-reperfusion injury. *Hepatobiliary & Pancreatic Diseases International*, 21, 94–98.
123. Yang, X., Lu, D., Wang, R., Lian, Z., Lin, Z., Zhuo, J., et al. (2021). Single-cell profiling reveals distinct immune phenotypes that contribute to ischaemia-reperfusion injury after steatotic liver transplantation. *Cell Proliferation*, 54, e13116.
124. DuBray, B. J., Jr., Conzen, K. D., Upadhya, G. A., Balachandran, P., Jia, J., Knolhoff, B. L., et al. (2012). Novel in vitro model for studying hepatic ischemia-reperfusion injury using liver cubes. *Science*, 332, 131–144.
125. Modis, K., Gero, D., Stangl, R., Rosero, O., Szijarto, A., Lotz, G., et al. (2013). Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury. *International Journal of Molecular Medicine*, 31, 437–446.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.